NCT03813095View on ClinicalTrials.gov

Exploratory Dose Ranging Study Assessing APH-1501 for the Treatment of Opioid Addiction

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

October 31, 2023

Primary Completion Date

September 30, 2025

Study Completion Date

December 31, 2025

Conditions
AddictionOpioid DependenceOpioid Withdrawal
Interventions
DRUG

APH-1501

The investigational drug product APH-1501 is CBD encapsulated in biodegradable polymer nanospheres, is a lyophilized powder intended for oral administration.

DRUG

Placebo

The placebo is a sterile pyrogen free lyophilized powder identical in appearance to the experimental drug product.

Sponsors

Lead Sponsor

Aphios
All Listed Sponsors
lead

Aphios

INDUSTRY

NCT03813095 - Exploratory Dose Ranging Study Assessing APH-1501 for the Treatment of Opioid Addiction | Biotech Hunter | Biotech Hunter